Kestra Director Raymond Cohen Buys $200K in Shares Amid Market Volatility

Kestra Medical Technologies director Raymond W. Cohen executed a $200,000 stock purchase on March 26, 2026, acquiring 10,000 shares in an open-market transaction. The purchase increased Cohen's direct ownership stake by 24.45% to 50,903 shares, representing 0.087% of outstanding shares post-transaction. The transaction was conducted directly with no use of derivative instruments, and all holdings remain in common shares. Cohen, a seasoned medical device industry veteran, previously led Axonics through its growth phase to a $3.7 billion acquisition by Boston Scientific in 2024. His experience navigating clinical sales cycles and reimbursement challenges positions him as a strategic board member for Kestra, which focuses on wearable cardiovascular solutions. This marks Cohen's second open-market purchase since joining the board in early 2025, both occurring during periods of depressed pricing. The company's business model centers on integrating wearable hardware with digital health services to improve cardiac patient outcomes. Key performance indicators for investors include contract acquisitions, reimbursement coverage expansions, and patient base growth beyond post-hospitalization windows. While Cohen's buying activity provides market context, analysts emphasize the need to evaluate Kestra's fundamentals independently. The Motley Fool Stock Advisor analysts recently highlighted 10 stocks for investment consideration, though Kestra was not included. Historical returns from the service's recommendations have significantly outperformed broader market indices, according to disclosures. Investors are advised to consider both insider activity and core business metrics when assessing potential investments in the medical device sector.